276 related articles for article (PubMed ID: 11823895)
1. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats.
Aravagiri M; Marder SR
Psychopharmacology (Berl); 2002 Feb; 159(4):424-31. PubMed ID: 11823895
[TBL] [Abstract][Full Text] [Related]
2. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.
Aravagiri M; Marder SR; Nuechterlein KH; Gitlin MJ
Ther Drug Monit; 2003 Dec; 25(6):657-64. PubMed ID: 14639051
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.
Bhatt J; Subbaiah G; Singh S
Rapid Commun Mass Spectrom; 2006; 20(14):2109-14. PubMed ID: 16775814
[TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers.
Belotto KC; Raposo NR; Ferreira AS; Gattaz WF
Clin Ther; 2010 Nov; 32(12):2106-15. PubMed ID: 21118746
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.
Aravagiri M; Marder SR
J Mass Spectrom; 2000 Jun; 35(6):718-24. PubMed ID: 10862124
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Aravagiri M; Marder SR; Wirshing D; Wirshing WC
Pharmacopsychiatry; 1998 May; 31(3):102-9. PubMed ID: 9657237
[TBL] [Abstract][Full Text] [Related]
7. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.
Aravagiri M; Yuwiler A; Marder SR
Psychopharmacology (Berl); 1998 Oct; 139(4):356-63. PubMed ID: 9809856
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone.
Titier K; Déridet E; Moore N
Toxicol Appl Pharmacol; 2002 Apr; 180(2):145-9. PubMed ID: 11969382
[TBL] [Abstract][Full Text] [Related]
9. Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.
Lee KS; Chae SW; Park JH; Park JH; Choi JM; Rhie SJ; Lee HJ
Xenobiotica; 2013 Mar; 43(3):303-10. PubMed ID: 23205514
[TBL] [Abstract][Full Text] [Related]
10. Effect of venlafaxine on the pharmacokinetics of risperidone.
Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
[TBL] [Abstract][Full Text] [Related]
11. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
Ding JJ; Jiao Z; Yu YQ; Shi XJ
Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
[TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.
Si T; Shu L; Liu Y; Su YA; Guo C; Zhang H
Hum Psychopharmacol; 2010 Jul; 25(5):404-9. PubMed ID: 20589922
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of risperidone in humans: a summary.
Heykants J; Huang ML; Mannens G; Meuldermans W; Snoeck E; Van Beijsterveldt L; Van Peer A; Woestenborghs R
J Clin Psychiatry; 1994 May; 55 Suppl():13-7. PubMed ID: 7520903
[TBL] [Abstract][Full Text] [Related]
14. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
[TBL] [Abstract][Full Text] [Related]
15. Validated LC-MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.
De Meulder M; Remmerie BM; de Vries R; Sips LL; Boom S; Hooijschuur EW; van de Merbel NC; Timmerman PM
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):8-16. PubMed ID: 18571483
[TBL] [Abstract][Full Text] [Related]
16. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
[TBL] [Abstract][Full Text] [Related]
17. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration.
Plomp TA; Wiersinga WM; Van Rossum JM; Maes RA
In Vivo; 1987; 1(5):265-79. PubMed ID: 2979794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
